2372.T Stock Flat at ¥2,790 on JPX, Oversold Bounce Setup May 2026

I’rom Group Co., Ltd. (2372.T) trades flat at ¥2,790 on the Tokyo Stock Exchange (JPX) as of May 8, 2026. The healthcare stock shows minimal intraday movement with volume at 22,800 shares, roughly 54% of its average. 2372.T stock has recovered significantly from its ¥1,750 year low, gaining 59.4% year-to-date. The company operates in medical care facilities, regenerative medicine, and clinical trial support across Japan. With a market cap of ¥33.8 billion, I’rom Group remains a niche player in the healthcare sector. Today’s flat action presents an interesting technical setup for oversold bounce traders monitoring this JPX-listed equity.

2372.T Stock Price Action and Technical Setup

I’rom Group’s 2372.T stock opened at ¥2,790 and has remained unchanged throughout the intraday session. The day’s range sits narrow between ¥2,790 and ¥2,793, suggesting consolidation near support levels. Volume remains subdued at 22,800 shares versus the 42,368-share average, indicating low participation today.

The stock’s Keltner Channels show the middle band at ¥2,790, with upper resistance at ¥2,793 and lower support at ¥2,787. This tight technical range reflects equilibrium between buyers and sellers. The Average True Range (ATR) of 1.50 indicates low volatility, typical of consolidation phases. Relative Volume sits at 0.54, confirming below-average trading activity. For oversold bounce traders, this flat action after the stock’s recovery from ¥1,750 suggests potential accumulation before the next directional move.

Valuation Metrics and Financial Health Assessment

2372.T trades at a P/E ratio of 23.87, above the Healthcare sector average of 22.88, reflecting premium pricing for the company’s growth profile. The price-to-book ratio of 2.64 indicates the stock trades at 2.6 times its tangible book value of ¥1,055 per share. Return on Equity stands at 11.36%, outperforming the sector average of 11.54%, showing solid profitability relative to shareholder capital.

The company maintains a current ratio of 1.23, indicating adequate short-term liquidity to cover obligations. However, the debt-to-equity ratio of 1.56 signals elevated leverage, with interest debt per share at ¥1,663. Free cash flow per share is negative at -¥295.60, a concern for long-term sustainability. Operating cash flow per share of ¥36.84 provides some cushion. Meyka AI rates 2372.T with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Market Sentiment and Trading Activity

Trading Activity remains subdued on 2372.T today, with volume at just 54% of the 42,368-share average. The Money Flow Index (MFI) sits at 50.00, indicating neutral sentiment with no clear buying or selling pressure. The Relative Vigor Index (RVI) also reads 50.00, confirming equilibrium in price momentum.

Liquidation pressure appears minimal, as the stock holds flat at ¥2,790 without breaking support levels. The On-Balance Volume (OBV) reads 0.00, suggesting no accumulation or distribution trend has established. This neutral technical backdrop creates an ideal environment for oversold bounce setups. Traders monitoring 2372.T should watch for volume expansion above 42,368 shares to confirm directional conviction. Track 2372.T on Meyka for real-time updates on volume and sentiment shifts.

Price Forecasts and Analyst Outlook

Meyka AI’s forecast model projects ¥2,671 as the yearly price target for 2372.T, implying downside of 4.3% from current levels. However, the three-year forecast rises to ¥2,951, suggesting recovery potential over a longer horizon. The five-year projection reaches ¥3,231, and the seven-year forecast climbs to ¥3,407, indicating long-term upside of 22.2% from today’s price.

These forecasts are model-based projections and not guarantees. The near-term downside projection reflects current valuation concerns and negative free cash flow. However, the improving outlook beyond three years suggests the market may eventually reward I’rom Group’s healthcare innovation focus. Earnings are scheduled for announcement on May 13, 2025, which could provide clarity on cash flow trends and operational performance. Investors should monitor this catalyst closely for potential volatility.

Final Thoughts

Irom Group Co., Ltd. (2372.T) trades at ¥2,790 with mixed signals. The stock shows consolidation after recovery, but negative free cash flow and high debt raise concerns. A B-grade rating and neutral technicals suggest holding. Meyka AI’s forecast of ¥2,671 indicates near-term pressure, though longer-term recovery is possible. The May 13 earnings announcement could be a catalyst. Traders should await volume confirmation above 42,368 shares before buying. Healthcare investors should monitor fundamentals closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.